Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab.

ABSTRACT:

Objective

To assess onset of effect in three placebo- or nonsteroidal anti-inflammatory drug (NSAID)-controlled trials of tanezumab in patients with moderate-to-severe osteoarthritis.

Methods

Post-hoc nonparametric Kaplan-Meier analyses were used to estimate median time to first improvement and to sustained improvement in Western Ontario and McMaster Universities Osteoarthritis Index domain (Pain, Physical Function, Stiffness) scores across a range of improvement thresholds (0-100%, in 5% increments). Time to first improvement was defined as the first week scores met the pre-specified threshold. Time to sustained improvement was defined as the first week scores met the pre-specified threshold and were sustained (on average) for the remainder of the treatment period.

Resul

SUBMITTER: Hunter DJ 

PROVIDER: S-EPMC9718254 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature